Headline: Moving the bar(rier) forward: the benefits of de-risking cytokine release syndrome

By SAMANTHA MCCLENAHAN Every breakthrough in cancer treatment brings hope, but it also comes with a staggering price, raising a critical question: how do we balance groundbreaking advances with the financial reality that could limit access for many patients?  Developing new cancer medications involves extensive research, clinical trials, and regulatory approvals; a lengthy process that…

Read More

How should family spillover effects be measured in HTA?

A paper by Campbell et al. (2024) provides some guidance. The authors developed a series of recommendations based on literature review, expert interviews and an expert workshop in order to support consistent and transparent evaluation and use of validated family spillover effects in health technology assessments (HTA) and cost-effectiveness analyses (CEA). The expert panel consisted…

Read More